News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
538,573 Results
Type
Article (40868)
Company Profile (139)
Press Release (497566)
Section
Business (145672)
Career Advice (1978)
Deals (28564)
Drug Delivery (77)
Drug Development (72724)
Employer Resources (144)
FDA (14260)
Job Trends (12126)
News (264703)
Policy (25614)
Tag
Academia (2524)
Alliances (37392)
Alzheimer's disease (1173)
Approvals (14182)
Artificial intelligence (109)
Bankruptcy (251)
Best Places to Work (10000)
Biotechnology (88)
Breast cancer (101)
Cancer (917)
Cardiovascular disease (83)
Career advice (1648)
Cell therapy (200)
Clinical research (57712)
Collaboration (310)
Compensation (114)
COVID-19 (2380)
C-suite (77)
Cystic fibrosis (77)
Data (873)
Diabetes (128)
Diagnostics (5364)
Earnings (53677)
Employer resources (129)
Events (75329)
Executive appointments (219)
FDA (14686)
Funding (295)
Gene therapy (158)
GLP-1 (566)
Government (4039)
Healthcare (16726)
Infectious disease (2454)
Inflammatory bowel disease (95)
Interviews (329)
IPO (13956)
Job creations (2407)
Job search strategy (1425)
Layoffs (330)
Legal (4898)
Lung cancer (162)
Manufacturing (143)
Medical device (11120)
Medtech (11124)
Mergers & acquisitions (14689)
Metabolic disorders (370)
Neuroscience (1416)
NextGen Class of 2024 (5797)
Non-profit (4146)
Northern California (1093)
Obesity (221)
Opinion (209)
Patents (82)
People (42415)
Phase I (17175)
Phase II (25638)
Phase III (19660)
Pipeline (251)
Postmarket research (2222)
Preclinical (7249)
Radiopharmaceuticals (256)
Rare diseases (197)
Real estate (4197)
Regulatory (17848)
Research institute (2194)
Resumes & cover letters (309)
Southern California (958)
Startups (3555)
United States (10004)
Vaccines (520)
Weight loss (171)
Date
Today (199)
Last 7 days (790)
Last 30 days (2765)
Last 365 days (31207)
2024 (27092)
2023 (34635)
2022 (44580)
2021 (48308)
2020 (46812)
2019 (40427)
2018 (30631)
2017 (28054)
2016 (26641)
2015 (30975)
2014 (22867)
2013 (18514)
2012 (19656)
2011 (20396)
2010 (18311)
Location
Africa (682)
Arizona (86)
Asia (32153)
Australia (5709)
California (2404)
Canada (1021)
China (199)
Colorado (113)
Connecticut (115)
Europe (74144)
Florida (356)
Georgia (85)
Illinois (281)
Indiana (147)
Kansas (85)
Maryland (452)
Massachusetts (1872)
Michigan (124)
Minnesota (154)
New Jersey (749)
New York (760)
North Carolina (580)
Northern California (1093)
Ohio (111)
Pennsylvania (613)
South America (957)
Southern California (958)
Texas (327)
Washington State (286)
538,573 Results for "ra capital associates".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management
Medicenna Therapeutics Corp. announced the closing of its previously announced CA$20 million investment by RA Capital Management, a multi-stage investment manager based in Boston, MA, by way of a non-brokered private placement.
April 30, 2024
·
5 min read
Biotech Beach
Qualigen Therapeutics’ Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN) today announces a poster presentation on its preclinical Novel Direct Pan-RAS Inhibitors was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California.
April 10, 2024
·
3 min read
Biotech Bay
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
Vaxart, Inc. announced that it has entered into a common stock purchase agreement with RA Capital Management for the sale of 15,384,615 shares of its common stock in a registered direct offering at an offering price of $0.65 per share.
January 16, 2024
·
6 min read
Drug Development
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
Erasca, Inc. announced it has entered into exclusive license agreements for two preclinical RAS programs—a potential best-in-class pan-RAS molecular glue and a potential first-in-class pan-KRAS inhibitor —and provided a pipeline update.
May 16, 2024
·
10 min read
Press Releases
Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise
October 25, 2024
·
10 min read
Drug Development
Celon Pharma Announces Results of Phase II clinical trial for CPL’ 116, a JAK/ROCK dual inhibitor in the treatment of Rheumatoid Arthritis (RA)
Celon Pharma S.A. (CLN.WA) today announced the successful completion of a Phase 2 trial a JAK/ROCK dual inhibitor in the treatment of Rheumatoid Arthritis (RA).
June 17, 2024
·
7 min read
Press Releases
Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors
October 24, 2024
·
5 min read
Drug Development
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, announced the publication of two peer-reviewed research papers in Nature.
April 8, 2024
·
8 min read
Drug Development
Sysmex Inostics’ RAS-RAF-SEQ Assay Receives New York State Department of Health CLEP Approval for Use in Clinical Trials
September 17, 2024
·
3 min read
Bio NC
Deep Blue Medical Receives Luisa Villalobos Award from Angel Capital Association as Innovative Life Science Company of 2024
Deep Blue Medical Advances announced today it has received the Luis Villalobos Award – Life Sciences from the Angel Capital Association (ACA), a professional association of more than 15,000 accredited angel investors and 250 angel groups, accredited platforms and family offices across North America.
May 21, 2024
·
2 min read
1 of 53,858
Next
